Skip to main content

Table 1 p53β and p53γ expression is associated with clinical markers

From: p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients

  All data
Response variable Predictor variable β Pvalue OR (95% CI)
p53β p53γ 1.01 0.008 2.75 (1.29 to 5.84)
p53γ p53m 1.47 0.002 4.33 (1.74 to 10.78)
  p53β 1.01 0.012 2.74 (1.24 to 6.04)
p53m p53γ 1.74 0.002 5.70 (1.92 to 16.93)
  p53β -0.02 0.970 0.98 (0.28 to 3.43)
  Tumour grade 3 2.85 <0.001 17.31 (4.02 to 74.45)
  ER -2.74 0.019 0.06 (0.01 to 0.64)
  PR 2.51 0.032 12.27 (1.25 to 120.74)
Overall survival p53m -1.44 0.017 0.24 (0.07 to 0.78)
  PR 1.48 0.014 4.41 (1.34 to 14.45)
  Tumour size -1.22 0.036 0.29 (0.09 to 0.93)
  p53γ -0.18 0.783 0.83 (0.22 to 3.10)
  p53β 1.15 0.082 3.17 (0.87 to 11.60)
Cancer recurrence p53m 1.25 0.013 0.29 (0.11 to 0.76)
  PR -1.26 0.009 3.52 (1.37 to 9.04)
  p53γ -0.28 0.636 1.33 (0.41 to 4.30)
  p53β -0.74 0.198 2.10 (0.68 to 6.47)
  1. Variables were analysed using binary logistic regression analysis utilising the backwards stepwise elimination method. Lymph node status, tumour grade, p53 mutation status (p53m), p53β, p53γ, human epidermal growth factor receptor 2 (HER2 or ErbB2), oestrogen receptor (ER) and progesterone receptor (PR) expression were included in the analyses as predictor variables. All independent significant associations between the predictor and response variables were identified (results of run 1). Dependent associations (results of runs 2, 3, 4, and so on) are omitted. Only results related to p53 and clinical outcome are presented. Results related to ER/PR, tumour grade and lymph node status are presented in Table S4 in Additional file 1. The β coefficients and the odds ratios (OR) with 95% confidence intervals (95% CI) are indicated.